期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性肾脏病患者糖皮质激素诱导的骨质疏松症防治研究进展

Prevention and treatment of glucocorticoid-induced osteoporosis in patients with chronic kidney disease
原文传递
导出
摘要 糖皮质激素诱导的骨质疏松症(GIOP)是糖皮质激素治疗的严重并发症之一,可增加骨折风险。糖皮质激素是慢性肾脏病患者的常用药物,激素和疾病本身均可干扰骨骼形成和再吸收平衡。GIOP的有效防治对患者预后至关重要。本文综述GIOP的临床防治进展。 Glucocorticoid-induced osteoporosis（GIOP） is one of the most serious complications in glucocorticoid use.It leads to an increasing risk of fractures.Glucocorticoids are widely used in patients with chronic kidney disease（CKD）.Glucocorticoids and those diseases can disturb the balance between bone formation and resorption.The prevention of GIOP can profoundly influence the prognosis of patients.This review focuses on the progress in prevention and treatment of GIOP in CKD.
作者 谷立杰 袁伟杰
机构地区 上海交通大学附属第一人民医院肾内科
出处 《世界临床药物》 CAS 2011年第11期646-651,共6页 World Clinical Drug
关键词 糖皮质激素诱导的骨质疏松症(GIOP) 不良反应 双膦酸盐 glucocorticoid-induced osteoporosis（GIOP） adverse reaction bisphosphonates
分类号 R97 [医药卫生—药品] R683 [医药卫生—骨科学]
  • 相关文献

参考文献34

  • 1Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid- induced osteoporosis: an update [J]. Trends Endocrinol Me- tab, 2006, 17 (4) : 144-149.
  • 2Gudbjomsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice[J]. Ann Rheum Dis, 2002, 61 (1) : 32-36.
  • 3van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis [J]. Osteoporosis Inter, 2002, 13 (10) : 777-787.
  • 4Compston JE. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis [J]. Current Rheumatology Reports, 2007, 9 (1) : 78-84.
  • 5Elder GJ. Nephrotic syndrome: don't forget the bones! [J]. Nephrology (Carlton), 2008, 13 (1) : 43-44.
  • 6王玲,袁伟杰,谷立杰,尚明花.慢性肾脏病患者骨代谢与尿蛋白量的关系[J].中华肾脏病杂志,2010,26(9):667-670. 被引量：5
  • 7Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis [J]. J Bone Miner Res, 2001, 16 (1) : 97-103.
  • 8Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone [J]. J Clin Invest, 1998, 102 (2) : 274-282.
  • 9Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk[J]. J Bone Miner Res, 2004, 19 (6):893-899.
  • 10Watts NB, Lewiecki EM, Miller PD, et al. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX) : what they mean to the bone densitometrist and bone technologist [J]. J Clin Densitom, 2008, 11 (4) : 473-477.

二级参考文献12

  • 1Elder GJ.Nephrotic syndrome:don't forget the bones!Nephrology (Carlton),2008,13:43-44.
  • 2Gulati S,Godbole M,Singh U,et al.Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J Kidney Dis,2003,41:1163-1169.
  • 3Wojnar J,Roszkowska-Blaim M.Dynamics of bone biochemical markers in nephrotic children treated with prednisone and metabolites of vitamin D.Przegl Lek,2007,64:552-558.
  • 4Xiang GD,Pu JH,Zhao LS,et al.Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes.Diabet Med,2009,26:397-403.
  • 5Gamero P.Biomarkers for osteoporosis management:utility in diagnosis,fracture risk prediction and therapy monitoring.Mol Diagn Ther,2008,12:157-170.
  • 6Lieben L,Callewaert F,Bouillon R.Bone and metabolism:a complex crosstalk.Horm Res,2009,71 Suppl 1:134-138.
  • 7Garnero P,Feneras M,Karsdal MA,et al.The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.J Bone Miner Res,2003,18:859-867.
  • 8Biyikli NK,Emre S,Sirin A,et al.Biochemical bone markers in nephrotic children.Pediatr Nephrol,2004,19:869-873.
  • 9Mittal SK,Dash SC,Tiwari SC,et al.Bone histology in patients with nephrotic syndrome and normal renal function.Kidney lnt,1999,55:1912-1919.
  • 10van Hoof HJ,de Sevaux RG,van Baelen H,et al.Relationship between free and total 1,25-dihydroxyvitamin D in oonditions of modified binding.Eur J Endocrinol,2001,144:391-396.

共引文献4

世界临床药物
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部